A real-world study on the expression and clinical application of IMP3 immunohistochemistry in bone tumors

IF 2.6 2区医学 Q2 PATHOLOGY

Human pathology Pub Date : 2025-08-23 DOI:10.1016/j.humpath.2025.105911

Qingzhu Wei, Lin Zhong, Hui Zhou, Lucen Jiang, Qi Wang, Dan Li, Qiao Yang

{"title":"A real-world study on the expression and clinical application of IMP3 immunohistochemistry in bone tumors","authors":"Qingzhu Wei, Lin Zhong, Hui Zhou, Lucen Jiang, Qi Wang, Dan Li, Qiao Yang","doi":"10.1016/j.humpath.2025.105911","DOIUrl":null,"url":null,"abstract":"<div><div>Previous studies have confirmed that insulin-like growth factor 2 mRNA-binding protein 3 (IMP3) is widely expressed in various malignant tumors. However, no systematic study has assessed the expression of IMP3 in bone tumors. We immunohistochemically examined 1381 bone tumor specimens for IMP3 expression, analyzed its differential expression among various types of bone tumors, and evaluated its potential application in surgical pathology. Our results demonstrated that IMP3 positivity was observed in 7.5 % (55/732) of benign bone tumors and 55.2 % (358/649) of malignant bone tumors, with statistically significant differences (<em>P</em> < 0.0001). Notably, higher levels of IMP3 expression were observed in high-grade malignant bone tumors than in their low-grade counterparts. The incidence of IMP3 positivity exceeds 80 % in diffuse large B-cell lymphoma, high-grade osteosarcoma, lymphoblastic lymphoma, and undifferentiated pleomorphic sarcoma. Additionally, we detected IMP3 positivity in 63.5 % (80/126) of metastatic bone cancers, specifically in 83.6 % (46/55) of lung cancers, 70 % (7/10) of liver cancers, and 87.5 % (7/8) of colorectal cancers. We also observed high levels of IMP3 expression in three benign bone tumor types: chondroblastoma, epithelioid hemangioma, and Langerhans cell histiocytosis. In conclusion, IMP3 immunostaining may serve as a diagnostic biomarker for malignant bone tumors, especially osteosarcoma and lymphoma. The high expression of IMP3 observed in bone metastases of lung cancer, liver cancer, and colorectal cancer indicates that IMP3 could be associated with bone metastasis in these malignancies. Future research should focus on elucidating the relationship between IMP3 expression and various clinicopathological parameters as well as prognostic outcomes in malignant bone tumors.</div></div>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":"164 ","pages":"Article 105911"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0046817725001984","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Previous studies have confirmed that insulin-like growth factor 2 mRNA-binding protein 3 (IMP3) is widely expressed in various malignant tumors. However, no systematic study has assessed the expression of IMP3 in bone tumors. We immunohistochemically examined 1381 bone tumor specimens for IMP3 expression, analyzed its differential expression among various types of bone tumors, and evaluated its potential application in surgical pathology. Our results demonstrated that IMP3 positivity was observed in 7.5 % (55/732) of benign bone tumors and 55.2 % (358/649) of malignant bone tumors, with statistically significant differences (P < 0.0001). Notably, higher levels of IMP3 expression were observed in high-grade malignant bone tumors than in their low-grade counterparts. The incidence of IMP3 positivity exceeds 80 % in diffuse large B-cell lymphoma, high-grade osteosarcoma, lymphoblastic lymphoma, and undifferentiated pleomorphic sarcoma. Additionally, we detected IMP3 positivity in 63.5 % (80/126) of metastatic bone cancers, specifically in 83.6 % (46/55) of lung cancers, 70 % (7/10) of liver cancers, and 87.5 % (7/8) of colorectal cancers. We also observed high levels of IMP3 expression in three benign bone tumor types: chondroblastoma, epithelioid hemangioma, and Langerhans cell histiocytosis. In conclusion, IMP3 immunostaining may serve as a diagnostic biomarker for malignant bone tumors, especially osteosarcoma and lymphoma. The high expression of IMP3 observed in bone metastases of lung cancer, liver cancer, and colorectal cancer indicates that IMP3 could be associated with bone metastasis in these malignancies. Future research should focus on elucidating the relationship between IMP3 expression and various clinicopathological parameters as well as prognostic outcomes in malignant bone tumors.

查看原文本刊更多论文

骨肿瘤中IMP3免疫组化表达及临床应用的真实世界研究

既往研究证实，胰岛素样生长因子2 mrna结合蛋白3 （insulin-like growth factor 2 mRNA-binding protein 3, IMP3）在多种恶性肿瘤中广泛表达。然而，没有系统的研究评估IMP3在骨肿瘤中的表达。我们用免疫组织化学方法检测了1381例骨肿瘤标本中IMP3的表达，分析了其在不同类型骨肿瘤中的表达差异，并评估了其在外科病理中的潜在应用。结果显示，良性骨肿瘤中有7.5%（55/732）、恶性骨肿瘤中有55.2%（358/649）出现IMP3阳性，差异有统计学意义（P < 0.0001）。值得注意的是，与低级别恶性骨肿瘤相比，在高级别恶性骨肿瘤中观察到更高水平的IMP3表达。在弥漫性大b细胞淋巴瘤、高级别骨肉瘤、淋巴母细胞淋巴瘤和未分化多形性肉瘤中，IMP3阳性的发生率超过80%。此外，我们在63.5%（80/126）的转移性骨癌中检测到IMP3阳性，特别是在83.6%（46/55）的肺癌，70%（7/10）的肝癌和87.5%（7/8）的结直肠癌中检测到IMP3阳性。我们还观察到三种良性骨肿瘤类型：成软骨细胞瘤、上皮样血管瘤和朗格汉斯细胞组织细胞增生症中IMP3的高水平表达。综上所述，IMP3免疫染色可作为恶性骨肿瘤，尤其是骨肉瘤和淋巴瘤的诊断生物标志物。在肺癌、肝癌和结直肠癌的骨转移中观察到IMP3的高表达，表明IMP3可能与这些恶性肿瘤的骨转移有关。未来的研究重点应放在阐明恶性骨肿瘤中IMP3表达与各种临床病理参数及预后的关系上。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human pathology 医学-病理学

CiteScore

5.30

自引率

6.10%

发文量

206

审稿时长

21 days

期刊介绍： Human Pathology is designed to bring information of clinicopathologic significance to human disease to the laboratory and clinical physician. It presents information drawn from morphologic and clinical laboratory studies with direct relevance to the understanding of human diseases. Papers published concern morphologic and clinicopathologic observations, reviews of diseases, analyses of problems in pathology, significant collections of case material and advances in concepts or techniques of value in the analysis and diagnosis of disease. Theoretical and experimental pathology and molecular biology pertinent to human disease are included. This critical journal is well illustrated with exceptional reproductions of photomicrographs and microscopic anatomy.